SCHEMBL22984010

SCHEMBL22984010

O=C(Nc1ncnc2c1ncn2[C@H]1C[C@@H](O)[C@H](CO)O1)c1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
SLC29A1 Q99808 1/20 0.59
HIF1A Q16665 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14733367 1.00 SLC29A1 (0.59) SLC29A1HIF1A
SCHEMBL29674600 1.00 SLC29A1 (0.59) SLC29A1HIF1A
SCHEMBL21539907 1.00 SLC29A1 (0.59) SLC29A1HIF1A
SCHEMBL264409 1.00 SLC29A1 (0.59) SLC29A1HIF1A
SCHEMBL264408 1.00 SLC29A1 (0.59) SLC29A1HIF1A
Water SCHEMBL29821265 0.99 SLC29A1 (0.58) SLC29A1HIF1A
SCHEMBL23881920 0.92 SLC29A1 (0.49) SLC29A1HIF1A
SCHEMBL31093228 0.92 SLC29A1 (0.49) SLC29A1
SCHEMBL9342970 0.92 SLC29A1 (0.49) SLC29A1HIF1A
SCHEMBL9342988 0.92 SLC29A1 (0.49) SLC29A1HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159922-A1 MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF IONIS PHARMACEUTICALS, INC. (US) 2023-05-25 US disclosed
US-20230159922-A1 MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF IONIS PHARMACEUTICALS, INC. (US) 2023-05-25 US disclosed
US-20230159922-A1 MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF IONIS PHARMACEUTICALS, INC. (US) 2023-05-25 US disclosed
EP-4013428-A1 MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF Ionis Pharmaceuticals, Inc. (US) 2022-06-22 EP disclosed
WO-2021030763-A1 MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF IONIS PHARMACEUTICALS, INC. (US) 2021-02-18 WO disclosed